Literature DB >> 14513565

Transfection of murine dendritic cell line (JAWS II) by a nonviral transfection reagent.

Shanjana Awasthi1, Rebecca A Cox.   

Abstract

Dendritic cells are the most potent antigen-presenting cells that initiate and modulate the host immune system. Based on their immunostimulatory activity, a variety of strategies have been developed to use dendritic cells as vaccines and immunotherapeutic agents against infection and cancer. Genetically modified dendritic cells are useful for immunotherapeutic purposes because of their sustained activity in vivo. However, transfection of dendritic cells with plasmid DNA has been very difficult. While the viral transfection is associated with nonspecific activation of dendritic cells, commonly used nonviral transfection reagents have a low efficiency of transfection. Here we describe an improved, simple, less time-consuming transfection protocol using the nonviral nonliposomal lipid polymer, TransIT-TKO transfection reagent, for transfecting murine dendritic cells (JAWS II) with the gene that encodes Coccidioides immitis antigen 2 (Ag2). The JAWS II cells were cotransfected with pHYG-enhanced green fluorescent protein (EGFP) and pVR1012-C. immitis Ag2 plasmid DNAs using TransIT-TKO reagent. We reproducibly obtained 30%-50% transfection efficiency. The transfected cells maintained their immature phenotype and were functionally active. In addition, the flexibility of this agent for expressing multiple antigens (GFP and C. immitis Ag2) offers an advantage of delivering multiple immunogens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14513565     DOI: 10.2144/03353dd03

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  12 in total

1.  EF24 suppresses maturation and inflammatory response in dendritic cells.

Authors:  Prachi Vilekar; Shanjana Awasthi; Aravindan Natarajan; Shrikant Anant; Vibhudutta Awasthi
Journal:  Int Immunol       Date:  2012-02-29       Impact factor: 4.823

2.  Corticotropin-releasing factor augments LPS-induced immune/inflammatory responses in JAWSII cells.

Authors:  Yue Hu; Meng Li; Bin Lu; Xi Wang; Chaoying Chen; Meng Zhang
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

3.  A toll-like receptor-4-interacting surfactant protein-A-derived peptide suppresses tumor necrosis factor-α release from mouse JAWS II dendritic cells.

Authors:  Shanjana Awasthi; Kevin Brown; Catherine King; Vibhudutta Awasthi; Rajkumar Bondugula
Journal:  J Pharmacol Exp Ther       Date:  2010-12-15       Impact factor: 4.030

4.  In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles.

Authors:  Xingfang Su; Jennifer Fricke; Daniel G Kavanagh; Darrell J Irvine
Journal:  Mol Pharm       Date:  2011-04-01       Impact factor: 4.939

5.  Adoptively transferred dendritic cells restore primary cell-mediated inflammatory competence to acutely malnourished weanling mice.

Authors:  Lyn Hillyer; Charlene Whitley; Amy Olver; Michelle Webster; Tessa Steevels; Bill Woodward
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

6.  Toll-like receptor 4-interacting SPA4 peptide suppresses the NLRP3 inflammasome in response to LPS and ATP stimuli.

Authors:  Vijay Ramani; Shanjana Awasthi
Journal:  J Leukoc Biol       Date:  2015-08-07       Impact factor: 4.962

7.  Biofilm and planktonic Enterococcus faecalis elicit different responses from host phagocytes in vitro.

Authors:  Kasturee Daw; Arto S Baghdayan; Shanjana Awasthi; Nathan Shankar
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03-08

8.  In vivo trafficking and immunostimulatory potential of an intranasally-administered primary dendritic cell-based vaccine.

Authors:  Prachi Vilekar; Vibhudutta Awasthi; Pallavi Lagisetty; Catherine King; Nathan Shankar; Shanjana Awasthi
Journal:  BMC Immunol       Date:  2010-12-10       Impact factor: 3.615

9.  Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes.

Authors:  Bojie Hu; Yan Zhang; Qing Zeng; Qian Han; Lijuan Zhang; Mian Liu; Xiaorong Li
Journal:  Int J Mol Sci       Date:  2014-01-22       Impact factor: 5.923

10.  Tumor targeting nanoparticle E749-57-HSP110-RGD elicits potent anti-tumor immune response in a CD8-dependent manner in cervical cancer-bearing mouse model.

Authors:  Yue Zhang; Faliang Ren; Bing Ni; Tao Jing; Jun Tang
Journal:  Hum Vaccin Immunother       Date:  2021-07-16       Impact factor: 4.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.